ReviewSeminars in immunopathology2022
Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.
Review in Seminars in immunopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The vascular endothelial growth factor as a candidate biomarker of systemic lupus erythematosus: a GRADE-assessed systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Inflammation as a key factor associated with kinesiophobia in a systemic lupus erythematosus patient population with a high frequency of Type D personality and central sensitization: a cross-sectional study.Rheumatology international · 2026Article
- Clinical features and outcomes of patients with anti-neutrophil cytoplasmic antibody-positive systemic lupus erythematosus from a single-center retrospective study.Clinical rheumatology · 2026Article
- Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?Rheumatology (Oxford, England) · 2026Review
- Flow-Mediated Skin Fluorescence Assessment of Microvascular Function in Connective Tissue Diseases: Associations with Nailfold Capillaroscopic Patterns.Journal of clinical medicine · 2026Article
- SLA and DDX60L as potential diagnostic biomarkers for subclinical atherosclerosis in systemic lupus erythematosus: a transcriptomic and clinical validation study.Clinical rheumatology · 2026Article
- Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.bioRxiv : the preprint server for biology · 2026Article
- Metabolomic Signatures and Advanced Echocardiography Highlight Clinical Risk and Early Cardiac Changes in Systemic Lupus Erythematosus: Six-Year Follow-Up.Metabolites · 2026Article
- Systemic lupus erythematosus-accelerated atherosclerosis: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Myocardial infarction in rheumatic diseases.Rheumatology international · 2025Review
- VOLupus · 2025Article
- Predictors of Mortality in Acute Myocardial Infarction Patients With Systemic Lupus Erythematosus.Cureus · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism.Frontiers in immunology · 2025Review
- Profiling Shared Cytotoxic Immune Signatures in SLE-Associated Coronary Injury Through Transcriptomics and Machine Learning.ImmunoTargets and therapy · 2025Article
- Cardiovascular and neurovascular complications in systemic lupus Erythematosus: A cross-sectional study of subclinical atherosclerosis and cognitive dysfunction.Bioinformation · 2025Article
- Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus.RMD open · 2024Article
- Two-dimensional speckle-tracking echocardiography in left ventricular systolic function in patients with systemic lupus erythematosus.Clinical rheumatology · 2024Article
- Mapping theme evolution and identifying hotspots in biomarkers of systemic lupus erythematosus based on global research.Biomarkers in medicine · 2024Article
- Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus (SLE) often features extensive cardiovascular (CV) comorbidity and patients with SLE are at significantly increased risk of CV event occurrence and CV-related mortality. While the specific mechanisms leading to this increased cardiovascular disease (CVD) risk remain to be fully characterized, this heightened risk cannot be fully explained by traditional CV risk factors and is likely driven by immunologic and inflammatory features of SLE. Widespread innate and adaptive immune dysregulation characterize SLE, and factors including excessive type I interferon burden, inappropriate formation and ineffective clearance of neutrophil extracellular traps, and autoantibody formation have been linked to clinical and metabolic features impacting CV risk in SLE and may represent pathogenic drivers of SLE-related CVD. Indeed, functional and phenotypic aberrations in almost every immune cell type are present in SLE and may impact CVD progression. As understanding of the contribution of SLE-specific factors to CVD in SLE improves, improved screening and monitoring of CV risk alongside development of therapeutic treatments aimed at prevention of CVD in SLE patients are required and remain the focus of several ongoing studies and lines of inquiry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.